Activmed Practices Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$40	1
2024	Research	$717,470	59
2023	Research	$571,763	251
2022	Research	$268,748	19
2021	Research	$24	1

Breakdown

Who paid Research payments · program years 2021–2025

Moderna TX, Inc. $1,555,526 329 payments
Pfizer Inc. $2,495 1 payment
GlaxoSmithKline, LLC. $24 1 payment

Studies the money was for Research payments · program years 2021–2025

A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age $859,661 239 payments
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $695,825 89 payments
A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $2,495 1 payment
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $40 1 payment
A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $24 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.